Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Robert Watson, a NIHR Academic Clinical Fellow in the laboratory of Benjamin Fairfax in the Department of Oncology. Robert was successful in his application for a CRUK pre-doctoral research bursary.

Pre-doctoral research bursaries are awarded biannually by Cancer Research UK to "provide short-term funding to allow clinicians and other health professionals to get involved in research projects early in their career". This scheme was ideal for Robert Watson, a junior doctor with an interest in academic research. He is currently taking a year out from his clinical training to conduct research in the laboratory of Benjamin Fairfax at the MRC WIMM, and is interested in applying for a PhD at a later date. "This CRUK grant will support my research this year" explains Rob "It will give me a chance to experience research and develop my skills, and hopefully gather preliminary data that will help me apply for a PhD".

The laboratory of Dr Benjamin Fairfax is examining the genetic changes that accompany the treatment of cancer with immunotherapies. During his time in the lab, Robert will be using sequencing techniques to investigate changes to the T cell repertoire during checkpoint inhibitor treatments. "I am very keen to work in the area of immunoncology and to further develop my skills in genetic medicine and computational biology, so this projects fits well with the lab's strategy and my own personal aims", says Robert. The successful bid will provide £25,000 towards the project's research expenses.

Similar stories

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.